1. Home
  2. BZFD vs RNTX Comparison

BZFD vs RNTX Comparison

Compare BZFD & RNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo BuzzFeed Inc.

BZFD

BuzzFeed Inc.

HOLD

Current Price

$0.60

Market Cap

33.5M

ML Signal

HOLD

RNTX

Rein Therapeutics Inc.

HOLD

Current Price

$1.25

Market Cap

30.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BZFD
RNTX
Founded
2006
2001
Country
United States
United States
Employees
N/A
11
Industry
Movies/Entertainment
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
33.5M
30.0M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
BZFD
RNTX
Price
$0.60
$1.25
Analyst Decision
Buy
Analyst Count
0
2
Target Price
N/A
$10.00
AVG Volume (30 Days)
208.1K
83.0K
Earning Date
05-06-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$1.69
N/A
Revenue Next Year
$108.06
N/A
P/E Ratio
$292.15
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.54
$1.02
52 Week High
$2.68
$2.22

Technical Indicators

Market Signals
Indicator
BZFD
RNTX
Relative Strength Index (RSI) 30.05 45.92
Support Level N/A $1.08
Resistance Level $0.84 $1.30
Average True Range (ATR) 0.05 0.15
MACD -0.00 -0.01
Stochastic Oscillator 27.50 27.78

Price Performance

Historical Comparison
BZFD
RNTX

About BZFD BuzzFeed Inc.

BuzzFeed Inc is a tech-powered, diversified media company that reaches hundreds of millions globally through its cross-platform news and entertainment network. The company produces articles, lists, quizzes, videos, and original series; lifestyle content through brands including Tasty, social food network; original reporting and investigative journalism through BuzzFeed News and HuffPost; an industry- affiliate business, strategic partnerships, licensing and product development through BuzzFeed Commerce; and original productions across broadcast, cable, SVOD, film and digital platforms for BuzzFeed Studios.

About RNTX Rein Therapeutics Inc.

Rein Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing therapies in orphan pulmonary and fibrosis indications, including two Phase 2-ready clinical assets. The company's product candidate includes LTI-03: a peptide for which company conducted a Phase 1b dose-ranging, placebo-controlled safety, tolerability, and pharmacodynamic biomarker activity trial in development for the treatment of Idiopathic Pulmonary Fibrosis; LTI-01: proenzyme that completed a Phase 2a dose-ranging, placebo-controlled trial and a Phase 1b safety, tolerability and proof of mechanism trial in loculated pleural effusion, or LPE, patients, an indication that has no approved drug treatment; and LTI-05 and others.

Share on Social Networks: